Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss
TARRYTOWN, N.Y., Sept. 25, 2023 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced…
Year: 2023
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that…
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that…
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain Cancer BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) — TransCode…
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Further Supports TTX-MC138 Application in Brain Cancer BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) — TransCode…
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or…
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or…
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery…
Valo Health and Novo Nordisk to collaborate to discover and develop novel treatments for cardiometabolic diseases using human data and artificial intelligence
Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery…
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON,…
PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101
Event to be held on Tuesday, October 3 from 8:00 to 9:00 AM EDT PRINCETON,…
Optiva MVNO Hubs Launched on Google Cloud, Offering BSS as a Service
Pre-integrated Optiva MVNO Hubs in key markets worldwide accelerate time-to-revenue for early-stage MVNOs to rapidly…
Optiva MVNO Hubs Launched on Google Cloud, Offering BSS as a Service
Pre-integrated Optiva MVNO Hubs in key markets worldwide accelerate time-to-revenue for early-stage MVNOs to rapidly…
5G Future Forum completes first-ever transatlantic real-time 5G holographic meeting using MATSUKO
LAS VEGAS, Sept. 25, 2023 (GLOBE NEWSWIRE) — The 5G Future Forum (5GFF) and MATSUKO…
5G Future Forum completes first-ever transatlantic real-time 5G holographic meeting using MATSUKO
LAS VEGAS, Sept. 25, 2023 (GLOBE NEWSWIRE) — The 5G Future Forum (5GFF) and MATSUKO…
Zero Trust Creator John Kindervag Joins Illumio to Accelerate Adoption of Zero Trust Segmentation
Former practitioner, analyst, and Palo Alto Networks executive on a mission to protect organizations by…
Zero Trust Creator John Kindervag Joins Illumio to Accelerate Adoption of Zero Trust Segmentation
Former practitioner, analyst, and Palo Alto Networks executive on a mission to protect organizations by…
TripleBlind Appoints Prat Moghe as CEO and Announces New AI Privacy Platform
Company’s patented AI Blinding™ technology delivers practical and proven solutions to unblock AI adoption in…